[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Johnson & Johnson Private Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100603783","phase-4-a-study-of-guselkumab-administered-subcutaneously-in-treatment-of-indian-participants-with-psoriatic-arthritis-psa-100603783",false,"NCT07141004","A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)","A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis","Inclusion Criteria:\n\n* Participants who have definite diagnosis of active psoriatic arthritis (PsA) (according to the ClASsification criteria for Psoriatic Arthritis \\[CASPAR\\]) prior to the first administration of study drug and have at least 1 of the PsA subsets: distal interphalangeal joint arthritis, polyarticular arthritis with the absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis\n* Participants who are negative for rheumatoid factors\n* Participants having inadequate response (defined by presence of active arthritis \\[presence of any swollen or any tender joint\\]) to standard therapies for 3 months at the highest recommended dose (e.g., conventional disease-modifying antirheumatic drugs \\[DMARDs\\] including methotrexate, apremilast, or nonsteroidal anti-inflammatory drugs \\[NSAIDs\\]), including biologics naïve patient or have failed, or were intolerant to one or more biological treatments \\[anti-TNF\u002FIL-17i\\]\n* Participants are considered eligible per the following Tuberculosis (TB) screening criteria:\n\n  1. Have no history of TB prior to screening AND\n  2. Have no signs or symptoms suggestive of active TB upon medical history and\u002For physical examination AND\n  3. Have had no recent close contact with a person with active TB, or if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study drug AND\n  4. Within 6 weeks prior to the first administration of study drug, have a negative QuantiFERON- TB Gold and a negative tuberculin skin test result, OR have a newly identified positive QuantiFERON-TB Gold or tuberculin skin test result during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study drug AND\n  5. Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of study drug and read by a qualified radiologist, with no evidence of current active TB or old inactive TB\n* Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG\n* A woman of childbearing potential must have a negative highly sensitive serum beta-hCG at screening visit\n\nExclusion Criteria:\n\n* History of latent or active granulomatous infection prior to screening\n* Have a known clinically significant hypersensitivity to guselkumab or to any of the excipients\n* Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study intervention\n* Has any known malignancy or has a history of malignancy, or a history of lymphoproliferative disease\n* Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of study intervention, during the study, or within 6 months after the last administration of study intervention","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.",[26],"Arthritis, Psoriatic","RECRUITING","2026-06-04",{"date":30,"type":31},"2026-06-05","ACTUAL",{"date":33,"type":31},"2025-08-12",{"date":35,"type":20},"2027-09-11",{"name":37,"class":38},"Johnson & Johnson Private Limited","INDUSTRY",10,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":53,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},"100595289","phase-4-a-study-to-assess-safety-of-teclistamab-in-indian-participants-with-relapsed-and-refractory-multiple-myeloma-100595289","NCT07030517","A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma","An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy","Inclusion Criteria:\n\n* Participant with diagnosed RRMM (as per IMWG definitions or investigator's discretion) who have received at least 3 prior lines of therapy including a proteasome inhibitor, an anti-CD 38 antibody and an immunomodulatory agent and have demonstrated disease progression on the last therapy\n* Documented evidence of progressive disease on last line of therapy based on investigator's determination of response by IMWG response criteria\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Contraceptive use by female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and not a woman of child bearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of less than \\[\\\u003C\\] 1 percent \\[%\\] per year), preferably with low user dependency, during the treatment period and for a period of 6 months after the last dose of study treatment and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during study period\n* A WOCBP must have a negative highly sensitive serum pregnancy test within 24 hours before the first dose of study treatment\n\nExclusion Criteria:\n\n* Participants who are not eligible to receive teclistamab as per the locally approved prescribing information\n* Received any prior B cell maturation antigen (BCMA)-directed therapy\n* Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain MRI, and lumbar cytology are required\n* Stroke, transient ischemic attack, or seizure within 6 months prior to screening\n* Participant had major surgery or had significant traumatic injury within 2 weeks prior to enrollment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study",{"count":48,"type":20},75,[23],"The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.",[52],"Multiple Myeloma",{"date":30,"type":31},{"date":55,"type":31},"2025-05-22",{"date":57,"type":20},"2027-06-20",{"name":37,"class":38},12,""]